Xanoxiban 15 mg 50 tablets

Tradename

Xanoxiban

Xanoxyban

Compound:

Each tablet contains:

Rivaroxaban 15 mg

Auxiliary components:

microcrystalline cellulose, croscarmellose sodium, hypromellose 5 cP (hydroxypropyl methylcellulose 2910), lactose monohydrate, magnesium stearate, sodium lauryl sulfate.

Properties

Rivaroxaban is a highly selective direct factor Xa inhibitor with high oral bioavailability.

Activation of factor X to form factor Xa via the intrinsic and extrinsic coagulation pathways plays a central role in the coagulation cascade. Factor Xa is a component of the emerging prothrombinase complex, the action of which leads to the conversion of prothrombin to thrombin. As a result, these reactions lead to the formation of a fibrin thrombus and activation of platelets by thrombin. One factor Xa molecule catalyzes the formation of more than 1000 thrombin molecules, which is called the «thrombin explosion». The reaction rate of factor Xa bound in prothrombinase increases by 300,000 times compared to that of free factor Xa, which provides a sharp jump in the level of thrombin. Selective factor Xa inhibitors can stop the «thrombin burst». Thus, rivaroxaban affects the results of some specific or general laboratory tests used to evaluate clotting systems.

Indications

— prevention of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation;

-treatment of deep vein thrombosis and pulmonary embolism and prevention of recurrence of DVT and PE.

Dosage and administration

Use the drug during meals.

Prevention of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation

The recommended dose is 20 mg 1 time / day.

Contraindications

— hypersensitivity to rivaroxaban or any excipients contained in the tablet;

— clinically significant active bleeding (for example, intracranial bleeding, gastrointestinal bleeding);

— an injury or condition associated with an increased risk of major bleeding (for example, an existing or recent gastrointestinal ulcer, the presence of malignant neoplasms with a high risk of bleeding, recent trauma to the brain or spinal cord, recent surgery on the brain, spinal cord or eyes, recent intracranial hemorrhage, diagnosed or suspected esophageal varicose veins, arteriovenous malformations, vascular aneurysms or large anomalies in the structure of the vessels of the brain or spinal cord);

Side effects

anemia (including relevant laboratory parameters) — ocular hemorrhage (including conjunctival hemorrhage) — gastrointestinal pain, dyspepsia, nausea, constipation, diarrhea, vomiting, bleeding gums, gastrointestinal bleeding (including rectal bleeding) — fever , peripheral edema, deterioration in general well-being (including weakness and asthenia) — hemorrhages after procedures (including postoperative anemia and bleeding from a wound), bruising — increased levels of transaminase — pain in the extremities. — dizziness, headache — bleeding from the urogenital tract (including hematuria, imenorrhagia), renal failure (including increased creatinine, increased urea levels) — epistaxis, hemoptysis — itching (including infrequent cases of generalized itching), rash, ecchymosis, skin and subcutaneous hemorrhages — arterial hypotension, hematoma .

Storage method:

At a temperature not higher than 30 degrees. In a dry place.